Alexis Krumme: Raising Awareness of Alloantibody Diseases in Pregnancy
Alexis Krumme, Director, Global Epidemiology, Immunology Therapy Area at Johnson & Johnson Innovative Medicine, shared a post on LinkedIn:
“This week, I’m proud to recognize High Risk Pregnancy Awareness Week and the maternal-fetal medicine and OBGYN communities working to support families facing complex pregnancies.
Alloantibody-driven diseases can cause serious, life-threatening complications for babies and pregnant individuals, but awareness and understanding remain limited.
At Johnson & Johnson Innovative Medicine, we’re proud to be advancing the field of maternal-fetal immunology, with a focus on driving awareness of hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Together with the broader patient, prenatal diagnostic, and healthcare communities, we are working toward solutions that meet the real needs of individuals and their families navigating high-risk pregnancies, including those impacted by alloantibody diseases like HDFN and FNAIT.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 07:35Anticoagulation and Contemporary Secondary Prevention of Thrombosis in Polycythemia Vera
-
Sep 5, 2026, 05:48Punit Mathur: From Leg Pain to Life-Threatening Pulmonary Embolism
-
Sep 5, 2026, 05:44Patrick Stonich: Identifying Missed Signs of Postoperative Pulmonary Embolism in Medical Record Reviews
-
Sep 5, 2026, 05:38Tom Van den Hoek: Warburg Effect Mimicking Refractory Shock in Cancer-Associated PE
-
Sep 5, 2026, 05:11Shinya Goto: Targeted Thrombolysis for High Risk Pulmonary Embolism
-
Sep 5, 2026, 04:56Opportunities for the Next Generation of Hematologists – American Society of Hematology
-
Sep 5, 2026, 04:51Samuel Nwokolo: The Bone Marrow Factory – Anatomy of Blood Production
-
Sep 5, 2026, 04:37Maryam Alaa Alsaid: Diagnostic Puzzle of Sickle Beta Thalassemia
-
Sep 5, 2026, 04:16Key Cardiovascular Insights from ESC Congress